when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

GILEAD · news · pharmadog

← back to GILEAD

News mentioning GILEAD

127 stories

29dWhy Pheast’s CEO has no regrets about transparent approach to R&D despite competitors circlingfiercebiotech

29d7 biopharma M&A deals where layoffs followedbiospace

Aug 18, 26Rebounding biotech funds expected to spur CDMO growth within yearbiospace

Aug 17, 26J&J hands lymphoma bispecific CAR T back to AbelZetabiospace

Aug 12, 26Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pillfiercebiotech

Aug 12, 26Boulevard starts up with $65M to pursue targeted autoimmune drugsbiopharma dive

Aug 12, 26Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlightbiospace

Aug 7, 26STAT+: Up and down the ladder: The latest comings and goingsstat

Aug 7, 26STAT+: Pharmalittle: We’re reading about Replimune’s melanoma drug, a Medicare policy change, and morestat

Aug 6, 26STAT+: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group assertsstat

Aug 6, 26STAT+: Pharmalittle: We’re reading about Moderna’s flu shot, a death in a gene-editing trial in China, and morestat

Aug 5, 26Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchbiopharma dive

Aug 5, 26Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mountsbiospace

Aug 5, 26STAT+: Moderna launches early trial of Ebola mRNA vaccinestat

Aug 5, 26STAT+: Pharmalittle: We’re reading about a Medicare pilot and orphan drugs, Pfizer cutbacks, and morestat

Aug 5, 264 potential biotech M&A targets, plus a pretty sure bet from J&Jbiospace

Aug 5, 26Gilead’s Yeztugo beats forecasts as HIV PrEP franchise exceeds $1Bendpoints

Aug 4, 26Ebola kills 1,700 in eastern Congo as the fastest-growing outbreak surgesstat

Aug 4, 26STAT+: Three biotechs with three news updatesstat

Aug 4, 26STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and morestat

Aug 4, 26Trans federal employees sue over revoked health coveragestat

Aug 4, 26STAT+: The latest orphan drug exemptions may not be warranted, analysis findsstat

Aug 4, 26STAT+: As Trump administration pushes court-ordered mental health care, a new report raises questionsstat

Aug 3, 26STAT+: California Supreme Court sides with Gilead in ‘duty’ to innovate casestat

Jul 31, 26‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spreefiercebiotech

Jul 30, 26J&J pays Sail $785M, charting course to possible in vivo CAR-T buyoutfiercebiotech

Jul 29, 26AbCellera, Vertex partner on next-gen T-cell engagersbiopharma dive

Jul 29, 26Atea's hep C pill equal to Gilead's; AbCellera inks second deal in two monthsendpoints

Jul 28, 26Eli Lilly tops new biopharma ranking on launch success, development speedfiercebiotech

Jul 28, 26Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trialfiercebiotech

← prevpage 2 of 5next →